Sign in
Active, not recruitingPhase 3

Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid therapy (BEZASCLER

Key facts

Who runs it
Assistance Publique Hopitaux De Paris
Where
France33 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
130 people, planned
Started
6 Apr 2021
Expected to end
6 Apr 2027
Type of study
Interventional
Record updated
9 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 36 criteriaShow less

Who can take part

  • Males or females ≥ 18 and ≤ 75 years
  • Large duct PSC verified by retrograde, operative, percutaneous or magnetic resonance cholangiography (MRC) demonstrating intrahepatic and /or extrahepatic biliary duct changes consistent with PSC
  • Colonoscopy (already done or scheduled before randomization) within the last 5 years (or within 6 months if IBD is associated to PSC) with neither cancer nor all-grade dysplasia or endoscopy of the ileal reservoir (already done or scheduled before randomization) within the last 2 years in patients with ileo-anal anastomosis
  • ALP ≥ 1.5 ULN
  • Traitement par l'AUDC (13-23 mg/kg/j) depuis ≥ 6 mois avant l'inclusion (Arrondi à l’unité le plus proche, par exemple 12.5 mg/kg/j arrondi à 13 mg/kg/j)
  • Using contraceptive in women of childbearing potential. Women of childbearing potential, i.e. fertile, following menarche and until becoming post-menopaused unless permanently sterile, who are sexually active have to apply a highly effective method of birth control with a low failure rate (i.e. less than 1% per year) when used constantly and correctly
  • Affiliation to a social security system (AME excepted)
  • Signed informed consent

Who cannot take part

  • Treatment with a fibrate within the last 3 months inclusion
  • Dosage change of treatment for associated IBD ≤3 months prior to inclusion
  • History of acute cholangitis in the last 3 months prior to inclusion or current acute cholangitis or suspected cholangiocarcinoma
  • Endoscopic treatment for bile duct stenosis ≤ 3 months prior to inclusion or planned within 3 months post randomization date
  • Prior liver transplantation
  • Current active IBD defined as either current use of systemic corticosteroid therapy > 10 mg/day or budesonide > 3 mg /day or immunosuppressive drugs (cyclosporine, tacrolimus, mycophenolate mofetil, mTor inhibitors, JAK inhibitors) or a partial Mayo score > 2 in patients with ulcerative colitis (UC), unclassed colitis or a Crohn’s Disease Activity Index (CDAI) > 150 in patients with Crohn’s disease (CD)
  • Current or history of colonic cancer or all-grade dysplasia described at the last colonoscopy (Patients with a history of colon cancer and treated by total colectomy without recurrence for at least 5 years are eligible)
  • Any other cause of liver damage ((positive test for HBV, HCV, or HIV, excessive alcohol consumption, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, celiac disease
  • History of or established or suspected hepatobiliary carcinoma
  • Current or recent history (within 2 years) of clinically detectable Ascites or digestive hemorrhage
  • History of malignancy diagnosed or treated within 2 years (recent localized treatment of squamous or non-invasive basal skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to Screening)
  • Known hypersensitivity to bezafibrate, any of the components of Befizal© or other fibrates
  • Current or recent history (within 2 years) of Autoimmune hepatitis defined by the presence of interface hepatitis documented on liver biopsy and at least 1 of the 2 following criteria: 1) AST or ALT > 5 ULN, 2) Positive anti smooth muscle auto antibodies or serum IgG > 1.5 ULN
  • Secondary causes of sclerosing cholangitis including IgG4-associated cholangitis (elevated serum IgG4 > 4 ULN)
  • Patient with congenital galactosemia, glucose malabsorption, or lactase deficiency because of presence of lactose in 400 mg SR tablets of bezafibrate and in placebo tablets
  • Renal insufficiency (clearance < 60 ml/min or serum creatinine level > 130 μmole/L)
  • Total bilirubin in the last 3 months > 50 μmole/L (3 mg/dl)
  • Gilbert syndrome defined as unconjugated bilirubinemia > LSN in the last 3 months (according to the laboratory reference value)
  • Albumin in the last 3 months < LLN (according to the laboratory reference value)
  • Platelets count in the last 3 months < 100000/mm3
  • ALT or AST > 5 ULN in the last 3 months
  • Child-Pugh score B or C
  • Any severe comorbidity that may reduce life expectancy
  • Known photosensitivity or photoallergy reactions to fibrate
  • Pregnancy (or desire for)
  • Breastfeeding
  • Participation in any other interventional study or in the exclusion period any other interventional study
  • Prothrombin index in the last 3 months < 70%

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the efficacy of 24-month treatment with bezafibrate (400 mg SR/d) versus placebo in addition to standard UDCA therapy in primary sclerosing cholangitis

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid therapy (BEZASCLER)
Record updated
9 November 2026